Ayahuasca – Religion, Life-style oder Droge?

Zusammenfassung

Ayahuasca ist ein psychoaktives Getränk, welches seit wahrscheinlich hunderten von Jahren von indigenen Kulturen des Amazonas-Beckens als Medizin und Hilfsmittel bei religiösen Ritualen benutzt wird. Durch den Rucksacktourismus fanden die Substanz und die damit verbundenen Rituale auch Verbreitung in der westlichen Welt. Anhand eines klinischen Fallberichts wird ein Abriss der Verwendung, der Pharmakologie, des rechtlichen Status und unerwünschter Wirkungen gegeben und diskutiert.

Abstract

Ayahuasca is a psychoactive drug which has been used by indigenous cultures in the amazonas basin for hundreds of years for medical and religious purpose. Backpackers who came in contact with ayahuasca exported its use in the western world and increased its popularity. By presenting a case report of a patient seeking medical help due to psychotic symptoms after having attended an ayahuasca ritual we give an short overview of pharmacology, legal status, use and side effects of the substance.

Schlüsselwörter

Ayahuasca - psychoaktive Droge - Pharmakologie - Gebrauch - rechtlicher Status

Key words

Ayahuasca - psychoactive drug - pharmacology - use - legal status

Publication History

Received: 14 August 2019

Accepted: 03 June 2020

Article published online:
16 June 2020

• Literatur

• 1 Apud I, Romano O. Medicine, religion and ayahuasca in Catalonia. Considering Ayahuasca Networks from a Medical Anthropology Network Perspective. Int J Drug Policy 2017; 39: 28-36
• 2 Luna LE. Vegetalismo: Shamanism among the mestizo population of the Peruvian Amazon. Studies in comparative religion. Stockholm: Almqvist & Wiksell International; 1986. https://www.worldcat.org/title/vegetalismo-shamanism-among-the-mestizo-population-of-the-peruvian-amazon/oclc/14712034
• 3 Bussman RW, Sharon D. Traditional medicinal plant use in Northern Peru: Tracking two thousand years of healing culture. J Ethnobiol Ethnomed 2006; Nov 7; 2: 47.
• 4 Balzer C. Ayahuasca Rituals in Germany. The First Steps of the Brazilian Santo Daime Religion in Europe. Curare. Zeitschrift Für Ethnomedizin Und Transkulturelle Psychiatrie 2005; 28: 57-70
• 5 Bouso JC, González D, Fondevila S. et al. Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study. PLoS One 2012; 7 (08) : e42421
• 6 Anbieter Ayahuasca. https://www.om-mij.nl/de/ayahuasca/ (zuletzt aufgerufen 20.03.2019)
• 7 Zinser H. Der Markt der Religionen. Fink, München: 1997 S. 62 ff. ISBN 978-3-7705-3257-5.
• 8 Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans: I. neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 1994; 51: 85-97
• 9 Strassman RJ, Qualls CR, Uhlenhuth EH. et al. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994; 51: 98-108
• 10 Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmakology 2018; 142: 200-218
• 11 Cameron LP, Olson DE. Dark Classics in Chemical Neuroscience: N,N-Dimethyltriptamine (DMT). ACS Chem Neurosci 2018; 9: 2344-2357
• 12 Ray TS. Psychedelics and the Human Receptorome. PLoS One 2010; 5 (02) : e9019
• 13 Sitaram BR, Lockett L, Blackmann GL. et al. In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltriptamine in the rat. Biochem Pharmacol 1987; 36: 1509-1512
• 14 Keiser MJ, Setola V, Irwin JJ. et al. Predicting new molecular targets for known drugs. Nature 2009; 426: 175-181
• 15 Glennon RA, Young R, Rosecrans JA. et al. Hallucinogenic agens as discriminative stimuli: A correlation with serotonin receptor affinity. Psychopharmacology (Berl) 1980; 68: 155-158
• 16 Riba J, Valle M, Urbano G. et al. Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics. J Pharmacol Exp Ther 2003; 306 (01) : 73-83
• 17 Dos Santos RG, Balthazar FM, Bouso JC. et al. The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning and neuroimaging. J Psychopharmacol 2016; 30 (12) : 1230-1247
• 18 Heise CW, Brooks DE. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015. J Med Toxicol 2017; 13: 245-248
• 19 De Araujo DB, Ribeiro S, Cecchi GA. et al. Seeing with the eyes shut: Neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp 2012; Nov. 33 (11) : 2550-2560.
• 20 Dos Santos RG. Safety and Side effects of ayahuasca in humans – an overview focusing on developmental toxicology. J Psychoactive Drugs 2013; 45: 68-78
• 21 United Nations. 1971 https://www.unodc.org/pdf/convention_1971_en.pdf (zuletzt aufgerufen am 11.02.2019)
• 22 Prue B. Prevalence of reported peyote use 1985-2010 effects of the American Indian Religious Freedom Act of 1994. Am J Addiction 2014; 23 (02) : 156-161
• 23 Feeney K. Peyote, Race, and Equal Protection in the United States. In: Labate B. Cavnar C. eds. Prohibition, Religious Freedom, and Human Rights: Regulating Traditional Drug Use. Springer, Berlin, Heidelberg: 2014
• 24 Griffin OH. The Role of the United States Supreme Court in Shaping Federal Drug Policy. Am J Crim Just 2014; 39: 660-679
• 25 Labate BC, Feeney K. Ayahuasca and the process of regulation in Brazil and internationally: Implications and challenges. Int J Drug Policy 2012; 23 (02) : 154-161
• 26 Internationale Klassifikation psychischer Störungen ICD-10, 4. Auflage. Hans Huber Verlag, Bern; 2000
• 27 Dos Santos RG, Bouso JC, MÁ A-C. et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Rev Clin Pharmacol 2018; 11 (09) : 889-902
• 28 Riba J, Anderer P, Jané F. et al. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: A functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 2004; 50 (01) : 89-101